IO Biotech, Inc. · OTC:IOBTQ
IO Biotech — Jefferies Healthcare Conference November 2025
28 slides from IO Biotech's conference presentation, Nov 18, 2025
Slide 1: Breaking Boundaries. Igniting Change.
Breaking Boundaries. Igniting Change. Nasdaq: IOBT Jefferies Healthcare Conference November 2025 Exhibit 99.1
Slide 2: Disclaimer | Forward Looking Statements
DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business pl
Slide 3: Cylembio is an investigational drug candidate not approved by FDA
Cylembio is an investigational drug candidate that has not been approved for marketing by the US FDA or other regulatory authorities.
Slide 4: IO Biotech | Breaking boundaries. Igniting change
IO Biotech | Breaking boundaries. Igniting change PHASE 3 RESULTS *Statistical significance threshold for this study was p≤0.045. 1. https://gco.iarc.fr/today/en/; 2. https://seer.cancer.gov/statfacts/html/melan.html; 3. Melanoma Research Alliance; 4. Larkin et al. N Engl J Med 2019;381:1535-1546; 5
Slide 5: The Melanoma Patient Journey
1. Melanoma of the Skin — Cancer Stat Facts; 2. https://seer.cancer.gov/statfacts/html/melan.html; Bajaj. J Natl Cancer Inst. 2020; Leeneman. EJC. 2021; Zhang. Adv Ther. 2023; Eggermont. J of Clin Onc. 2019; Eggermont. NEJM. 2022; Wolchok. J Clin Oncol. 2022; Miller, CA Cancer J Clin, 2019; National
Slide 6: Cylembio in First-Line Advanced Melanoma
Cylembio in First-Line Advanced Melanoma
Slide 7: Phase 3 trial design
Primary endpoint PFS by central review Secondary/exploratory endpoints ORR, DRR, CRR, OS, DoR, TTR, DCR Incidence of AEs and SAEs Quality of life Biomarkers in blood and tumor tissue will also be assessed Stratification Endpoints Randomization 407 enrolled across >100 sites in Europe, Australia, Sou
Slide 8: Cylembio demonstrated PFS improvement across virtually all subgroups
PHASE 3 TRIAL | Cylembio demonstrated PFS improvement across virtually all pre-specified subgroups and stratification factors Topline results released August 2025 *Statistical significance threshold for this study was p≤0.045. **Post-hoc analysis. Source: Data on file. Overall Survival trend favorin
Slide 9: Early Separation of PFS Curves – Widening Over Time
PHASE 3 TRIAL | Early Separation of PFS Curves at 3 Months – Widening Over Time Source: Company data on file. Kaplan-Meier estimate of PFS in ITT determined by BICR per RECISTv1.1 and stratified by PD-L1 status and disease stage
Slide 10: Trend in Overall Survival Benefiting Cylembio
PHASE 3 TRIAL | Trend in Overall Survival Benefiting Cylembio (not yet mature) separating early and widening HR, 0.79; 95% CI, 0.57 to 1.10 OS not mature HR 0.79 is in line with 12 month OS data reported from other IO combinations Source: Company data on file. Kaplan–Meier estimate of OS in ITT and
Slide 11: Safety Data
SAFETY DATA | Treatment with Cylembio did not add significant systemic toxicity compared to patients treated with pembrolizumab monotherapy Source: Company data on file. Acronyms: AE, adverse event; CTCAE, common terminology criteria for adverse events; MedDRA, medical dictionary for medical regulat
Slide 12: Market Opportunity in Advanced Melanoma
MARKET OPPORTUNITY IN ADVANCED MELANOMA | Cylembio® profile has potential to fulfill significant unmet needs and drive market leadership 1. https://gco.iarc.fr/today/en/; 2. https://seer.cancer.gov/statfacts/html/melan.html; 3. Melanoma Research Alliance; 4. Larkin et al. N Engl J Med 2019;381:1535-
Slide 13: Cylembio is an ideal combination partner candidate
Cylembio is an ideal combination partner candidate that we believe could deliver clinical activity without tolerability issues: IO102-IO103 has demonstrated improvement in PFS, trend towards long and durable response including in hard-to-treat subgroups, with favorable safety across a number of comb
Slide 14: Proposed Phase 3 trial design
Primary endpoint PFS by central review Secondary/exploratory endpoints OS, DoR, TTR, DCR Incidence of AEs and SAEs Quality of life Biomarkers in blood and tumor tissue will also be assessed Stratification Endpoints Phase 2 (step 1) Randomization Advanced melanoma Unresectable stage III Metastatic st
Slide 15: Our Pipeline: NSCLC, SCCHN, Neoadjuvant/adjuvant
Our Pipeline: NSCLC, SCCHN, Neoadjuvant/adjuvant
Slide 16: Pipeline
Product candidates Line of therapy/ indication Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways & next steps Cylembio® IO102-IO103 Targets: IDO1, PD-L1 IOB-013, IOB-023: First Line Advanced Melanoma* Cylembio demonstrated clinical improvement in PFS, narrowly missed statistical significance in IOB-013
Slide 17: Totality of clinical data in NSCLC, SCCHN and melanoma
FIRST-LINE METASTATIC NSCLC Results from Phase 2 (SITC 2024) ORR 55% unconfirmed/48% confirmed; mPFS 8.1 months Benchmark** ORR 39%, mPFS 6.5 months Status Encouraging ORR and PFS and no progression in nearly half of patients FIRST-LINE RECURRENT/ METASTATIC SCCHN Results from Phase 2 (ESMO 2024) OR
Slide 18: Addressable Patients
ADDRESSABLE PATIENTS | Cylembio with potential to redefine treatment of hard-to-treat solid tumors and expanding beyond 1L advanced melanoma Total addressable patients (US) >100,000 patients1 ~40,000 patients2 ~15,000 patients3 Expand to earlier lines 3 Peri-operative SCCHN Peri-operative melanoma A
Slide 19: Platform Potential
PLATFORM POTENTIAL | The proposed adaptive Phase 3 trial aims to give IOBT the potential to jump ahead with the goal of becoming the first triple combination therapy New proposed Phase 3 study (IOB-023) Designed to be well positioned in evolving/future landscape (SoC) Goal is to demonstrate long/dur
Slide 20: Pre-clinical pipeline: Arginase 1 and TGFβ programs
T-win platform can be used outside oncology with opportunity to investigate infectious diseases Two preclinical programs in solid tumors showing evidence of anti-tumor activity as monotherapy or in combination PRE-CLINICAL PIPELINE | Expanding the clinical portfolio with Arginase 1 program; IND fili
Slide 21: Our T-win Platform
win® Platform OurT (6)
Slide 22: Mechanism of Action
MECHANISM OF ACTION | IO Biotech’s T-win® vaccine approach supported by improvement in PFS demonstrated with Cylembio in IOB-013* Subcutaneous injection with T-win® therapeutic cancer vaccine T-win vaccine activates T cells with a dual mechanism of action T cells attack both target expressing tumor
Slide 23: Off-the-Shelf Treatment
OFF-THE-SHELF TREATMENT | Cylembio is designed to ensure patients access to treatment without delay* * Compared to a personalized vaccine ** E.g., anti PD-1 treatment Characteristics of an off-the-shelf vaccine enhancing patients and physicians’ experience Directly available… at site of care, in bot
Slide 24: Outlook
Outlook (6)
Slide 25: Milestones
MILESTONES | Several important milestones expected through 2026 Cylembio | 1L Advanced Melanoma Top-line readout of primary endpoint in phase 3 study, 3Q25, narrowly missed statistical significance Enrollment completed in January 2025 Initial data from neoadjuvant/adjuvant Ph2 available 2H25; presen
Slide 26: IO Biotech Team
IO Biotech Team (6)
Slide 27: The Team
THE TEAM | We have a strong management team with large biopharma and biotech experience Mai-Britt Zocca, PhD President and Chief Executive Officer Amy Sullivan, MBA Chief Financial Officer Dan Mannix, PhD SVP Regulatory Devin Smith General Counsel Qasim Ahmad, MD Chief Medical Officer Faiçal Miyara,
Slide 28: Board of Directors and Scientific Advisory Board
THE TEAM | Our management team is supported by the Board of Directors and the Scientific Advisory Board Peter Hirth, Ph.D. Chairman Kathleen Sereda Glaub, M.B.A. Member Christian Elling, Ph.D. Member – Lundbeckfonden Heidi Hunter Member David V. Smith, M.B.A. Member Mai-Britt Zocca, Ph.D. Founder, P
IO Biotech — Jefferies Healthcare Conference November 2025 on 6ix